Association of metformin use with cancer incidence and mortality: A meta-analysis

Cancer Epidemiology

Volumn 37, Issue 3, 2013, Pages 207-218

  Zhang, Pengpeng ^a   Li, Hao ^a   Tan, Xianhua ^b   Chen, Lili ^a   Wang, Shumei ^a  

^a SHANDONG UNIVERSITY   (China)

^b Shandong Sports Science Research Center   (China)

Author keywords

Overall cancer; Site specific cancer; Summary

Indexed keywords

METFORMIN;

ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; COLORECTAL CANCER; DRUG EFFECT; DRUG USE; HUMAN; LIVER CANCER; META ANALYSIS; PANCREAS CANCER; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; METFORMIN; NEOPLASMS; SURVIVAL RATE;

EID: 84876334434     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2012.12.009     Document Type: Article

References (67)

1. Howlett H.C. Metformin in the management of type 2 diabetes. Diabetic Medicine: A Journal of the British Diabetic Association 1989, 6(2):179-180.
2. Ruiter R., Visser L.E., van Herk-Sukel M.P., Coebergh J.W., Haak H.R., Geelhoed-Duijvestijn P.H., et al. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes Care 2012, 35(1):119-124.
3. Lee M.S., Hsu C.C., Wahlqvist M.L., Tsai H.N., Chang Y.H., Huang Y.C. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer 2011, 11:20.
4. Bosco J.L., Antonsen S., Sorensen H.T., Pedersen L., Lash T.L. Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 2011, 20(1):101-111.
5. Hassan M.M., Curley S.A., Li D., Kaseb A., Davila M., Abdalla E.K., et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 2010, 116(8):1938-1946.
6. Bo S., Ciccone G., Rosato R., Villois P., Appendino G., Ghigo E., et al. Cancer mortality reduction and metformin: a retrospective cohort study in type 2 diabetic patients. Diabetes, Obesity & Metabolism 2012, 14(1):23-29.
7. He X., Esteva F.J., Ensor J., Hortobagyi G.N., Lee M.H., Yeung S.C. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+breast cancer. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO 2012, 23(7):1771-1780.
8. Lee J.H., Kim T.I., Jeon S.M., Hong S.P., Cheon J.H., Kim W.H. The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. International Journal of Cancer 2011, 131(3):752-759.
9. Landman G.W., Kleefstra N., van Hateren K.J., Groenier K.H., Gans R.O., Bilo H.J. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 2010, 33(2):322-326.
10. Cusi K., Consoli A., DeFronzo R.A. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. The Journal of Clinical Endocrinology and Metabolism 1996, 81(11):4059-4067.
11. Pagano G., Tagliaferro V., Carta Q., Caselle M.T., Bozzo C., Vitelli F., et al. Metformin reduces insulin requirement in Type 1 (insulin-dependent) diabetes. Diabetologia 1983, 24(5):351-354.
12. Giovannucci E. Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. The American Journal of Clinical Nutrition 2007, 86(3):s836-s842.
13. Giovannucci E., Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 2007, 132(6):2208-2225.
14. Xue F., Michels K.B. Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. The American Journal of Clinical Nutrition 2007, 86(3):s823-s835.
15. Vazquez-Martin A., Oliveras-Ferraros C., del Barco S., Martin-Castillo B., Menendez J.A. The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO 2009, 20(3):592-595.
16. Martin-Castillo B., Vazquez-Martin A., Oliveras-Ferraros C., Menendez J.A. Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle (Georgetown, Tex) 2010, 9(6):1057-1064.
17. Grenader T., Goldberg A., Shavit L. Metformin as an addition to conventional chemotherapy in breast cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2009, 27(35):e259. [author reply e260].
18. Kourelis T.V., Siegel R.D. Metformin and cancer: new applications for an old drug. Medical Oncology (Northwood, London, England) 2011, 29(2):1314-1327.
19. Vazquez-Martin A., Oliveras-Ferraros C., Del Barco S., Martin-Castillo B., Menendez J.A. The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. Breast Cancer Research and Treatment 2011, 126(2):355-364.
20. Li D., Yeung S-CJ, Hassan M.M. Anti-diabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009, 137:7.
21. Currie C.J., Poole C.D., Gale E.A. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009, 52(9):1766-1777.
22. Bodmer M., Meier C., Krahenbuhl S., Jick S.S., Meier C.R. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 2010, 33(6):1304-1308.
23. Bayraktar S., Hernadez-Aya L.F., Lei X., Meric-Bernstam F., Litton J.K., Hsu L., et al. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer 2012, 118(5):1202-1211.
24. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ (Clinical Research Ed) 2003, 327(7414):557-560.
25. Baldwin S.A., Christian S., Berkeljon A., Shadish W.R. The effects of family therapies for adolescent delinquency and substance abuse: a meta-analysis. Journal of Marital and Family Therapy 2012, 38(1):281-304.
26. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical Research Ed) 1997, 315(7109):629-634.
27. Piccinni C., Motola D., Marchesini G., Poluzzi E. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care 2011, 34(6):1369-1371.
28. Tseng C.H. Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan. Diabetologia 2011, 54(8):2009-2015.
29. Bodmer M., Becker C., Meier C., Jick S.S., Meier C.R. Use of metformin and the risk of ovarian cancer: a case-control analysis. Gynecologic Oncology 2011, 123(2):200-204.
30. Romero I.L., McCormick A., McEwen K.A., Park S., Karrison T., Yamada S.D., et al. Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstetrics and Gynecology 2012, 119(1):61-67.
31. Libby G., Donnelly L.A., Donnan P.T., Alessi D.R., Morris A.D., Evans J.M. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009, 32(9):1620-1625.
32. Morden N.E., Liu S.K., Smith J., Mackenzie T.A., Skinner J., Korc M. Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients. Diabetes Care 2011, 34(9):1965-1971.
33. Bowker S.L., Yasui Y., Veugelers P., Johnson J.A. Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure. Diabetologia 2010, 53(8):1631-1637.
34. Yang X., So W.Y., Ma R.C., Yu L.W., Ko G.T., Kong A.P., et al. Use of sulphonylurea and cancer in type 2 diabetes-The Hong Kong Diabetes Registry. Diabetes Research and Clinical Practice 2010, 90(3):343-351.
35. Baur D.M., Klotsche J., Hamnvik O.P., Sievers C., Pieper L., Wittchen H.U., et al. Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort. Metabolism: Clinical and Experimental 2011, 60(10):1363-1371.
36. Hense H.W., Kajuter H., Wellmann J., Batzler W.U. Cancer incidence in type 2 diabetes patients - first results from a feasibility study of the D2C cohort. Diabetology & Metabolic Syndrome 2011, 3(1):15.
37. Monami M., Colombi C., Balzi D., Dicembrini I., Giannini S., Melani C., et al. Metformin and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 2011, 34(1):129-131.
38. Currie C.J., Poole C.D., Jenkins-Jones S., Gale E.A., Johnson J.A., Morgan C.L. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 2012, 35(2):299-304.
39. Geraldine N., Marc A., Carla T., Chantal M., Stefaan B., Welcome W., et al. Relation between diabetes, metformin treatment and the occurrence of malignancies in a Belgian primary care setting. Diabetes Research and Clinical Practice 2012, 97(2):331-336.
40. Nkontchou G., Cosson E., Aout M., Mahmoudi A., Bourcier V., Charif I., et al. Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. The Journal of Clinical Endocrinology and Metabolism 2011, 96(8):2601-2608.
41. Donadon V., Balbi M., Mas M.D., Casarin P., Zanette G. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver International: Official Journal of the International Association for the Study of the Liver 2010, 30(5):750-758.
42. Chen T.M., Lin C.C., Huang P.T., Wen C.F. Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation. Journal of Gastroenterology and Hepatology 2011, 26(5):858-865.
43. Little M.W., Pugh T.F., Carey F.J. The potential protective effect of metformin against pancreatic cancer preliminary results from a casecontrol study in two UK centres. Gut 2011, 60. (10.1136).
44. Bodmer M., Becker C., Meier C., Jick S.S., Meier C.R. Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis. The American Journal of Gastroenterology 2012, 107(4):620-626.
45. Sadeghi N., Abbruzzese J.L., Yeung S.C., Hassan M., Li D. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2012, 18(10):2905-2912.
46. Yang Y.X., Hennessy S., Lewis J.D. Type 2 diabetes mellitus and the risk of colorectal cancer. Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association 2005, 3(6):587-594.
47. Chung Y.W., Han D.S., Park K.H., Eun C.S., Yoo K.S., Park C.K. Insulin therapy and colorectal adenoma risk among patients with Type 2 diabetes mellitus: a case-control study in Korea. Diseases of the Colon and Rectum 2008, 51(5):593-597.
48. Tseng C.H. Diabetes, metformin use, and colon cancer: a population-based cohort study in Taiwan. European Journal of Endocrinology/European Federation of Endocrine Societies 2012, 167(3):409-416.
49. Bodmer M., Becker C., Meier C., Jick S.S., Meier C.R. Use of metformin is not associated with a decreased risk of colorectal cancer: a case-control analysis. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 2012, 21(2):280-286.
50. Chlebowski R.T., McTiernan A., Wactawski-Wende J., Manson J.E., Aragaki A.K., Rohan T., et al. Diabetes, metformin, and breast cancer in postmenopausal women. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2012, 30(23):2844-2852.
51. Murtola T.J., Tammela T.L., Lahtela J., Auvinen A. Antidiabetic medication and prostate cancer risk: a population-based case-control study. American Journal of Epidemiology 2008, 168(8):925-931.
52. Wright J.L., Stanford J.L. Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes & Control 2009, 20(9):1617-1622.
53. Azoulay L., Dell'Aniello S., Gagnon B., Pollak M., Suissa S. Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 2011, 20(2):337-344.
54. He X.X., Tu S.M., Lee M.H., Yeung S.C. Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO 2011, 22(12):2640-2645.
55. Lehman D.M., Lorenzo C., Hernandez J., Wang C.P. Statin use as a moderator of metformin effect on risk for prostate cancer among type 2 diabetic patients. Diabetes Care 2012, 35(5):1002-1007.
56. Gao S., Yang W.S., Gao J., Wang J., Xiang Y.B. A meta-analysis of cohort studies on the association between diabetes and the risk of primary liver cancer. Zhonghua Yu Fang Yi Xue Za Zhi 2010, 44(8):711-716.
57. Ben Q., Xu M., Ning X., Liu J., Hong S., Huang W., et al. Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. European Journal of Cancer (Oxford, England: 1990) 2011, 47(13):1928-1937.
58. Sun L., Yu S. Diabetes mellitus is an independent risk factor for colorectal cancer. Digestive Diseases and Sciences 2012, 57(6):1586-1597.
59. Liao S., Li J., Wei W., Wang L., Zhang Y., Wang C., et al. Association between diabetes mellitus and breast cancer risk: a meta-analysis of the literature. Asian Pacific Journal of Cancer Prevention: APJCP 2011, 12(4):1061-1065.
60. Caporicci D., Mori A., Pepi R., Lapi E. Effects of dimethylbiguanide (metformin) on peripheral insulin clearance and lipid biosynthesis in obese dyslipidemic subjects with and without diabetes mellitus. La Clinica Terapeutica 1979, 88(4):372-386.
61. Decensi A., Puntoni M., Goodwin P., Cazzaniga M., Gennari A., Bonanni B., et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prevention Research (Philadelphia, Pa) 2010, 3(11):1451-1461.
62. Feng Y.H., Wu C.L., Shiau A.L., Lee J.C., Chang J.G., Lu P.J., et al. microRNA-21-mediated regulation of Sprouty2 protein expression enhances the cytotoxic effect of 5-fluorouracil and metformin in colon cancer cells. International Journal of Molecular Medicine 2012, 29(5):920-926.
63. Vazquez-Martin A., Oliveras-Ferraros C., Cufi S., Del Barco S., Martin-Castillo B., Menendez J.A. Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. Cell Cycle (Georgetown, Tex) 2010, 9(18):3807-3814.
64. Hemkens L.G., Grouven U., Bender R., Gunster C., Gutschmidt S., Selke G.W., et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009, 52(9):1732-1744.
65. Hitron A., Adams V., Talbert J., Steinke D. The influence of antidiabetic medications on the development and progression of prostate cancer. Cancer Epidemiology 2012, 36(4):e243-e250.
66. Kasper Jocelyn S., Liu Yan, Giovannucci Edward Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. International Journal of Cancer 2009, 124(March (6)):1398-1403.
67. Noto H., Goto A., Tsujimoto T., Noda M. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS ONE 2012, 7(3):e33411.